계명대학교 의학도서관 Repository

Clinical Outcomes Following Letrozole Treatment according to Estrogen Receptor Expression in Postmenopausal Women: LETTER Study (KBCSG-006)

Metadata Downloads
Author(s)
Sung Gwe AhnSeok Jin NamSei Hyun AhnYongsik JungHeung Kyu ParkSoo Jung LeeSung Soo KangWonshik HanKyong Hwa ParkYong Lai ParkJihyoun LeeHyun Jo YounJun Hyun KimYoungbum YooJeong-Yoon SongByung Kyun KoGeumhee GwakMin Sung ChungSung Yong KimSeo Heon ChoDoyil KimMyung-Chul ChangByung In MoonLee Su KimSei Joong KimMin Ho ParkTae Hyun KimJihyoung ChoCheol Wan LimYoung Tae BaeGyungyub GongYoung Kyung BaeAhwon LeeJoon Jeong
Keimyung Author(s)
Cho, Ji Hyoung
Department
Dept. of Surgery (외과학)
Journal Title
Journal of Breast Cancer
Issued Date
2021
Volume
24
Issue
2
Keyword
Breast neoplasmsLetrozolePostmenopauseReceptorsestrogen
Abstract
Purpose:
In this trial, we investigated the efficacy and safety of adjuvant letrozole for hormone receptor (HR)-positive breast cancer. Here, we report the clinical outcome in postmenopausal women with HR-positive breast cancer treated with adjuvant letrozole according to estrogen receptor (ER) expression levels.

Methods:
In this multi-institutional, open-label, observational study, postmenopausal patients with HR-positive breast cancer received adjuvant letrozole (2.5 mg/daily) for 5 years unless they experienced disease progression or unacceptable toxicity or withdrew their consent. The patients were stratified into the following 3 groups according to ER expression levels using a modified Allred score (AS): low, intermediate, and high (AS 3–4, 5–6, and 7–8, respectively). ER expression was centrally reviewed. The primary objective was the 5-year disease-free survival (DFS) rate.

Results:
Between April 25, 2010, and February 5, 2014, 440 patients were enrolled. With a median follow-up of 62.0 months, the 5-year DFS rate in all patients was 94.2% (95% confidence interval [CI], 91.8–96.6). The 5-year DFS and recurrence-free survival (RFS) rates did not differ according to ER expression; the 5-year DFS rates were 94.3% and 94.1%in the low-to-intermediate and high expression groups, respectively (p = 0.6), and the corresponding 5-year RFS rates were 95.7% and 95.4%, respectively (p = 0.7). Furthermore, 25 patients discontinued letrozole because of drug toxicity.

Conclusion:
Treatment with adjuvant letrozole showed very favorable treatment outcomes and good tolerability among Korean postmenopausal women with ER-positive breast cancer, independent of ER expression.
Keimyung Author(s)(Kor)
조지형
Publisher
School of Medicine (의과대학)
Citation
Sung Gwe Ahn et al. (2021). Clinical Outcomes Following Letrozole Treatment according to Estrogen Receptor Expression in Postmenopausal Women: LETTER Study (KBCSG-006). Journal of Breast Cancer, 24(2), 164–174. doi: 10.4048/jbc.2021.24.e17
Type
Article
ISSN
2092--9900
Source
https://ejbc.kr/DOIx.php?id=10.4048/jbc.2021.24.e17
DOI
10.4048/jbc.2021.24.e17
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/43506
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Surgery (외과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.